GO
Loading...

Merck & Co Inc

More

  • Merck And "Sex and the City" Strategy: Did It Work? Tuesday, 22 Jul 2008 | 2:38 PM ET
    Sex and The the City

    Recently I blogged about Merck advertising its cervical cancer vaccine Gardasil to a captive audience during trailers for the "Sex and the City" movie.

  • Oil Buoys Stocks but Techs Drag Tuesday, 22 Jul 2008 | 2:01 PM ET

    Stocks advanced, buoyed by a sharp drop in oil prices, but technology stocks dragged on the market after disappointing earnings from Apple and Texas Instruments.

  • Farrell: Touching Bottom in this Bear Market? Tuesday, 22 Jul 2008 | 10:56 AM ET
    Vince Farrell

    The average bear market shows a decline of 30%, but then has an average 30% plus bounce when the bottom is reached. We are off more than 20% so it's possible the end is in sight.

  • vytorin_logo.jpg

    Yesterday while covering the press conference about the new study on Merck and Schering-Plough's Vytorin I quoted the lead researcher, Dr. Terje Pedersen of Ulleval University Hospital in Oslo, Norway, who said--and this is a direct quote: "However, we had a disturbing finding when we looked at safety."

  • All Signs Point To Weaker Open Monday, 21 Jul 2008 | 6:08 PM ET
    graphic_word_ofthe_street.jpg

    Based on the action after hours it looks like a rough open on Tuesday. What's the "Word on the Street?"

  • Banks Snap Winning Streak, Stocks Slide Monday, 21 Jul 2008 | 5:22 PM ET

    Stocks slipped as the bank rally that has stretched four sessions appeared to run out of steam ahead of Wachovia's report. Merck fell following disappointing results from a cholesterol-drug study.

  • Schering-Plough Profit Falls but Tops Forecasts Monday, 21 Jul 2008 | 5:09 PM ET
    schering_plough_earnings.jpg

    Schering-Plough, whose shares fell earlier after its Vytorin cholesterol fighter failed another study, said its earnings fell 23 percent but beat forecasts.

  • Merck Limits Guidance; Posts In-Line Results Monday, 21 Jul 2008 | 5:03 PM ET
    merck_earnings.jpg

    Merck  on Monday said it was not providing long-time financial forecasts as it assesses the impact of another failed study result for its Vytorin cholesterol fighter, which it produces with Schering Plough.

  • Bulls Find No Joy In After Hours Session Monday, 21 Jul 2008 | 5:03 PM ET

    1) American Express reported a notable miss ($0.56 vs. expectations of $0.83), and it's not hard to see where the bulk of the miss came from. a $600 million ($374 after-tax) addition to U.S. lending credit reserves.

  • vytorin_logo.jpg

    Vytorin, a cholesterol drug marketed by drugmakers Merck and Schering-Plough, failed to meet the main goals in a new study, released Monday.

  • Bank Rally Fizzles; Merck Shares Fall Monday, 21 Jul 2008 | 3:29 PM ET

    Stocks slipped as the morning bank rally fizzled. Merck fell following disappointing results from a cholesterol-drug study.

  • Bank Rally Loses Steam; Merck Skids Monday, 21 Jul 2008 | 2:37 PM ET

    Stocks slipped as the bank rally that has stretched four sessions appeared to fizzle ahead of Wachovia's report. Merck fell following disappointing results from a cholesterol-drug study.

  • roche_logo.jpg

    The buyout offer from Swiss drug giant Roche has shares of DNA trading at their highest level in about two-and-a-half years and according to CNBC stock-stat maven, Robert Hum, if they close up at least 8.88% it'll be their biggest one-day percentage gain since April 15, 2005.

  • Banks, Miners Lift Euro Shares, Roche Drags Monday, 21 Jul 2008 | 12:44 PM ET

    Gains in financial stocks lifted European shares on Monday as markets cheered Bank of America's stronger-than-expected quarterly results, while declines in Roche offset some of the gains.

  • Banks Log 4th Straight Rally; Dow Wobbles Monday, 21 Jul 2008 | 11:55 AM ET

    Stocks advanced, led by a fourth straight rally in bank stocks after Bank of America beat expectations. News of a potential pharma deal also gave the market a boost.

  • Merck, Schering Delay Earnings For Vytorin Update Monday, 21 Jul 2008 | 10:10 AM ET
    vytorin_logo.jpg

    Merck and Schering-Plough delayed the release of their quarterly  financial results so investors could first learn the outcome of a new study of their Vytorin cholesterol fighter, and both drug makers' shares fell on jitters about the impending trial data.

  • European Shares Set to Inch Higher, Earnings Eyed Monday, 21 Jul 2008 | 1:34 AM ET

    European stocks were set to inch higher on Monday, extending a three-session rally, as investors brace for a flurry of  corporate earnings from U.S. bellwethers such as Apple , Merck  and Bank of America.

  • Elan In Double Trouble? Friday, 11 Jul 2008 | 11:32 AM ET
    Elan

    A few weeks ago I blogged about a couple analysts cautioning investors that shares of Irish drugmaker Elan would be volatile surrounding the Alzheimer's conference the end of this month.That has certainly proven to be the case, especially today as the second firm this week initiates coverage of the stock, but this time with a "Sell" rating.

  • Pfizer, Merck And Lilly Partner Up To Get "Enlightened" Thursday, 10 Jul 2008 | 10:30 AM ET
    pfizer_hq.jpg

    Big pharma makes strange bedfellows. Pfizer, Merck and Eli Lilly this morning announced they've launched a joint venture of sorts called, "Enlight Biosciences". They're doing it with the help of the Boston-based VC firm PureTech Ventures.

  • Stocks Drop Into Official Bear Market Wednesday, 9 Jul 2008 | 6:06 PM ET
    graphic_word_ofthe_street.jpg

    The S&P closed 20% below its all-time high set in October, making it the last of the three major U.S. stock indexes to fall into a bear market. What's the "Word on the Street?"